Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

• Status: Completed
• Trial end date: 2014-03-01

Summary

Primary Objective:

• To evaluate the effect of single and repeated administration of rifapentine given as daily or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and tenofovir given as a fixed dose combination (ATRIPLA™ ).

Secondary Objective:

• To evaluate the safety and tolerability of concomitant administration of rifapentine and ATRIPLA™ given to HIV+ patients

• Phase: Phase 1

Details

• Lead Sponsor: Sanofi
• Treatments: Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Rifampin; Rifapentine; Tenofovir